Formycon is a world-leading, independent developer of high-quality biosimilars, meaning follow-on products to biopharmaceutical medicines already on the market.
Our focus is on treatments in ophthalmology and immunology as well as for other key chronic diseases. Our company’s activities span the entire range from technical- pharmaceutical development to clinical trials all the way through to preparation and submission of dossiers for regulatory approval.
We develop biosimilar medicines to meet the high standards of the world’s most stringently regulated markets: the European Union, the United States, Canada, Japan and Australia. We will continue to expand our position as a globally operating company in the growth market of biosimilars in line with our growth strategy.
Fraunhoferstraße 15, 82152 Martinsried/Planegg – Germany
Keep yourself informed with the most recent updates on FinancialReports, IPOs, product advancements, and other significant news.